Mesuximide: Difference between revisions

	WikiDoc Resources for Mesuximide
Articles
Most recent articles on Mesuximide Most cited articles on Mesuximide Review articles on Mesuximide Articles on Mesuximide in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Mesuximide Images of Mesuximide Photos of Mesuximide Podcasts & MP3s on Mesuximide Videos on Mesuximide
Evidence Based Medicine
Cochrane Collaboration on Mesuximide Bandolier on Mesuximide TRIP on Mesuximide
Clinical Trials
Ongoing Trials on Mesuximide at Clinical Trials.gov Trial results on Mesuximide Clinical Trials on Mesuximide at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Mesuximide NICE Guidance on Mesuximide NHS PRODIGY Guidance FDA on Mesuximide CDC on Mesuximide
Books
Books on Mesuximide
News
Mesuximide in the news Be alerted to news on Mesuximide News trends on Mesuximide
Commentary
Blogs on Mesuximide
Definitions
Definitions of Mesuximide
Patient Resources / Community
Patient resources on Mesuximide Discussion groups on Mesuximide Patient Handouts on Mesuximide Directions to Hospitals Treating Mesuximide Risk calculators and risk factors for Mesuximide
Healthcare Provider Resources
Symptoms of Mesuximide Causes & Risk Factors for Mesuximide Diagnostic studies for Mesuximide Treatment of Mesuximide
Continuing Medical Education (CME)
CME Programs on Mesuximide
International
Mesuximide en Espanol Mesuximide en Francais
Business
Mesuximide in the Marketplace Patents on Mesuximide
Experimental / Informatics
List of terms related to Mesuximide

Mesuximide
Clinical data
AHFS/Drugs.com	Consumer Drug Information
MedlinePlus	a682028
Pregnancy; category	US: C (Risk not ruled out) ; ;
Routes of; administration	Oral
ATC code	N03AD03 (WHO) ;
Legal status
Legal status	US: ℞-only ;
Pharmacokinetic data
Metabolism	Hepatic (demethylation and glucuronidation)
Elimination half-life	1.4–2.6 hours (mesuximide); 28–38 hours (active metabolite)
Excretion	Renal
Identifiers
	IUPAC name (RS)-1,3-dimethyl-3-phenyl-pyrrolidine-2,5-dione;
CAS Number	77-41-8 ;
PubChem CID	6476;
DrugBank	DB05246 ;
ChemSpider	6231 ;
UNII	0G76K8X6C0;
KEGG	D00404 ;
ChEMBL	ChEMBL697 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C12H13NO2
Molar mass	203.237 g/mol
3D model (JSmol)	Interactive image;
	SMILES O=C2N(C(=O)CC2(c1ccccc1)C)C;
	InChI InChI=1S/C12H13NO2/c1-12(9-6-4-3-5-7-9)8-10(14)13(2)11(12)15/h3-7H,8H2,1-2H3 ; Key:AJXPJJZHWIXJCJ-UHFFFAOYSA-N ;
(what is this?) (verify)

← Older edit Newer edit →

VisualWikitext

Revision as of 18:45, 9 April 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Mesuximide (or methsuximide, methosuximide) is a succinimide anticonvulsant medication. It is sold as a racemate by Pfizer under the tradenames Petinutin (Switzerland)^[1] and Celontin (United States).^[2] The therapeutic efficacy of methosuximide is largely due to its pharmacologically active metabolite, N-desmethylmethosuximide, which has a longer half-life and attains much higher plasma levels than its parent.^[3]

References

↑ Pfizer AG (2005). "Petinutin (Mésuximide)". Official Pfizer AG Website (in French). Retrieved August 21, 2006. ^{[dead link]}
↑ Pfizer Inc. (2008). "Celontin (methsuximide capsules, USP)". Official Pfizer Inc. Website. Retrieved November 21, 2014.
↑ Porter RJ, Penry JK, Lacy JR, Newmark ME, Kupferberg HJ. Plasma concentrations of phensuximide, methosuximide, and their metabolites in relation to clinical efficacy. Neurology 29: 1509-1513, 1979.

Template:Anticonvulsants

This anticonvulsant-related article is a stub. You can help Wikipedia by expanding it.

[Petinutin-1] Pfizer AG (2005). "Petinutin (Mésuximide)". Official Pfizer AG Website (in French). Retrieved August 21, 2006. ^{[dead link]}

[Celontin-2] Pfizer Inc. (2008). "Celontin (methsuximide capsules, USP)". Official Pfizer Inc. Website. Retrieved November 21, 2014.

[3] Porter RJ, Penry JK, Lacy JR, Newmark ME, Kupferberg HJ. Plasma concentrations of phensuximide, methosuximide, and their metabolites in relation to clinical efficacy. Neurology 29: 1509-1513, 1979.

[1]

[2]

[3]

@@ Line 3: / Line 3: @@
 | verifiedrevid = 411374493
 | IUPAC_name = (''RS'')-1,3-dimethyl-3-phenyl-pyrrolidine-2,5-dione
-| image = Mesuximide.svg
+| image = Mesuximide.png
 | width = 250px
 | imagename = 1 : 1 mixture (racemate)
@@ Line 50: / Line 50: @@
 | StdInChIKey = AJXPJJZHWIXJCJ-UHFFFAOYSA-N
 }}
+              __NOTOC__
+{{SI}}
+{{CMG}}
+==Overview==
 '''Mesuximide''' (or '''methsuximide''', '''methosuximide''') is a [[succinimide]] [[anticonvulsant]] medication. It is sold as a [[racemate]] by [[Pfizer]] under the tradenames '''Petinutin''' (Switzerland)<ref name=Petinutin>{{cite web | author = Pfizer AG | year = 2005 | url = http://www.pfizer.ch/internet/fr/home/products/central_nervous_system/epilepsy/petinutin_mesuximid.html | title = Petinutin (Mésuximide) | work = Official Pfizer AG Website | accessdate = August 21, 2006 | language = French }} {{Dead link|date=November 2010|bot=H3llBot}}</ref> and '''Celontin''' (United States).<ref name=Celontin>{{cite web | author = Pfizer Inc. | year = 2008 | url = http://labeling.pfizer.com/ShowLabeling.aspx?id=555 | title = Celontin (methsuximide capsules, USP) | work = Official Pfizer Inc. Website | accessdate = November 21, 2014 | language =  }}</ref> The therapeutic efficacy of methosuximide is largely due to its pharmacologically active metabolite, N-desmethylmethosuximide, which has a longer half-life and attains much higher plasma levels than its parent.<ref>Porter RJ, Penry JK, Lacy JR, Newmark ME, Kupferberg HJ. Plasma concentrations of phensuximide, methosuximide, and their metabolites in relation to clinical efficacy. Neurology 29: 1509-1513, 1979.</ref>
 ==References==
-{{Reflist}}
+{{Reflist|2}}
 {{Anticonvulsants}}
 [[Category:Anticonvulsants]]
-[[Category:Succinimides]]
+[[Category:Durg]]
 {{anticonvulsant-stub}}

Mesuximide: Difference between revisions

Revision as of 18:45, 9 April 2015

Overview

References

Navigation menu

Search